MA49255A - Format d'anticorps hétérodimère multispécifique ciblant au moins cd3 et hsa - Google Patents

Format d'anticorps hétérodimère multispécifique ciblant au moins cd3 et hsa

Info

Publication number
MA49255A
MA49255A MA049255A MA49255A MA49255A MA 49255 A MA49255 A MA 49255A MA 049255 A MA049255 A MA 049255A MA 49255 A MA49255 A MA 49255A MA 49255 A MA49255 A MA 49255A
Authority
MA
Morocco
Prior art keywords
hsa
antibody format
heterodimeric antibody
specific heterodimeric
format targeting
Prior art date
Application number
MA049255A
Other languages
English (en)
Inventor
Tea Gunde
Christian Hess
Sebastian Meyer
Alexandre Simonin
David Urech
Original Assignee
Numab Therapeutics AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Numab Therapeutics AG filed Critical Numab Therapeutics AG
Publication of MA49255A publication Critical patent/MA49255A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA049255A 2017-06-05 2018-06-04 Format d'anticorps hétérodimère multispécifique ciblant au moins cd3 et hsa MA49255A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762515293P 2017-06-05 2017-06-05

Publications (1)

Publication Number Publication Date
MA49255A true MA49255A (fr) 2020-04-15

Family

ID=60473421

Family Applications (1)

Application Number Title Priority Date Filing Date
MA049255A MA49255A (fr) 2017-06-05 2018-06-04 Format d'anticorps hétérodimère multispécifique ciblant au moins cd3 et hsa

Country Status (11)

Country Link
US (1) US12098203B2 (fr)
EP (1) EP3635014B1 (fr)
JP (1) JP7549961B2 (fr)
KR (1) KR102771043B1 (fr)
CN (1) CN110719918B (fr)
AU (1) AU2018280683B2 (fr)
CA (1) CA3065868C (fr)
ES (1) ES2967739T3 (fr)
MA (1) MA49255A (fr)
SG (1) SG11201911527QA (fr)
WO (1) WO2018224443A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3634998B8 (fr) * 2017-06-05 2025-04-09 Numab Therapeutics AG Anticorps anti cd3 epsilon
MA49249A (fr) * 2017-06-05 2021-04-14 Numab Therapeutics AG Nouveaux anticorps anti-hsa
AU2019250692A1 (en) 2018-04-13 2020-11-05 Sangamo Therapeutics France Chimeric antigen receptor specific for Interleukin-23 receptor
EP3897851A2 (fr) * 2018-12-17 2021-10-27 Revitope Limited Recruteur de cellules immunitaires jumelles
EP4591879A3 (fr) * 2019-01-31 2025-10-22 Numab Therapeutics AG Anticorps multispécifiques ayant une spécificité pour tnfa et il-17a, anticorps ciblant il-17a, et leurs procédés d'utilisation
EP3808766A1 (fr) * 2019-10-15 2021-04-21 Sangamo Therapeutics France Récepteur d'antigène chimérique spécifique pour récepteur de l'interleukine 23
EP3816185A1 (fr) * 2019-11-04 2021-05-05 Numab Therapeutics AG Anticorps multi-spécifique contra pd-l1 et antigène associé à une tumeur
EP3915580A1 (fr) * 2020-05-29 2021-12-01 Numab Therapeutics AG Anticorps multi-spécifique
KR20230018397A (ko) * 2020-05-29 2023-02-07 누맙 세러퓨틱스 아게 다중 특이적 항체
JP2024504471A (ja) * 2021-02-02 2024-01-31 ヌマブ セラピューティックス アーゲー Ｒｏｒ１およびｃｄ３に対する特異性を有する多重特異性抗体
CN117003872A (zh) * 2022-04-28 2023-11-07 北京天广实生物技术股份有限公司 含有突变轻链可变区骨架的单链抗体片段
EP4638508A1 (fr) * 2022-12-23 2025-10-29 Chugai Seiyaku Kabushiki Kaisha Complexe polypeptidique dont l'activité de liaison à l'antigène varie en fonction de la concentration d'une protéine plasmatique
WO2025136820A1 (fr) * 2023-12-18 2025-06-26 Regents Of The University Of Minnesota Complexes de récepteur de cytokine poly-antigène (paccs), compositions et procédés d'utilisation

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2176484T3 (es) 1995-08-18 2002-12-01 Morphosys Ag Bancos de proteinas/(poli)peptidos.
EP1293514B1 (fr) 2001-09-14 2006-11-29 Affimed Therapeutics AG Multimères d'anticorps Fv monocaténaires en tandem
MY192182A (en) 2009-06-26 2022-08-04 Regeneron Pharma Readily isolated bispecific antibodies with native immunoglobulin format
WO2013013700A1 (fr) * 2011-07-22 2013-01-31 Affimed Therapeutics Ag Molécule fv multivalente de liaison à un antigène
MX353382B (es) * 2012-03-01 2018-01-10 Amgen Res Munich Gmbh Moleculas de union polipeptido de larga duracion.
WO2015172800A1 (fr) * 2014-05-12 2015-11-19 Numab Ag Nouvelles molécules multispécifiques et nouvelles méthodes de traitement basées sur ces molécules multispécifiques
IL243311B (en) 2013-06-26 2022-07-01 Numab Therapeutics AG New frameworks for antibodies
EP3060579A1 (fr) 2013-10-25 2016-08-31 Numab AG Constructions bispécifiques et leur utilisation dans le traitement de diverses maladies
WO2016184570A1 (fr) * 2015-05-18 2016-11-24 Numab Ag Nouvelles méthodes de traitement sur la base de molécules multifonctionnelles
US9708412B2 (en) * 2015-05-21 2017-07-18 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
IL293435B1 (en) 2015-06-15 2026-04-01 Numab Therapeutics AG Heterodimeric multispecific antibody format
MA49249A (fr) * 2017-06-05 2021-04-14 Numab Therapeutics AG Nouveaux anticorps anti-hsa
EP3634998B8 (fr) * 2017-06-05 2025-04-09 Numab Therapeutics AG Anticorps anti cd3 epsilon
CN109651507B (zh) * 2017-10-12 2021-11-26 瑞阳(苏州)生物科技有限公司 一种激动型4-1bb单克隆抗体

Also Published As

Publication number Publication date
AU2018280683B2 (en) 2025-05-22
WO2018224443A1 (fr) 2018-12-13
AU2018280683A1 (en) 2019-10-17
CA3065868A1 (fr) 2018-12-13
EP3635014C0 (fr) 2023-09-27
KR20200013230A (ko) 2020-02-06
SG11201911527QA (en) 2020-01-30
EP3635014B1 (fr) 2023-09-27
JP2020522267A (ja) 2020-07-30
KR102771043B1 (ko) 2025-02-26
US20200181263A1 (en) 2020-06-11
EP3635014A1 (fr) 2020-04-15
CN110719918B (zh) 2024-05-24
CN110719918A (zh) 2020-01-21
ES2967739T3 (es) 2024-05-03
JP7549961B2 (ja) 2024-09-12
CA3065868C (fr) 2024-06-04
US12098203B2 (en) 2024-09-24

Similar Documents

Publication Publication Date Title
MA49255A (fr) Format d'anticorps hétérodimère multispécifique ciblant au moins cd3 et hsa
MA71409A (fr) Constructions d'anticorps pour dll3 et cd3
MA53330A (fr) Constructions d'anticorps pour cldn18.2 et cd3
IL282496A (en) Epcam antibodies, activatable antibodies, and immunoconjugates, and uses thereof
FR24C1050I1 (fr) Récepteurs d'antigènes chimériques basés sur des anticorps à domaine unique et leurs méthodes d'utilisation
EP3618871A4 (fr) Formulations d'anticorps anti-lag3 etco-formulations d'anticorps anti-lag3 et d'anticorps anti-pd-1
MA43197A (fr) Constructions d'anticorps bispécifiques pour cdh3 et cd3
IL289354A (en) Anti-cd154 antibodies and uses thereof
ZA202104518B (en) Cd3 antibody and pharmaceutical use thereof
EP3470430A4 (fr) Anticorps de liaison au récepteur de l'interleukine 4
EP3442576A4 (fr) Anticorps b7-h6 à haute affinité et fragments d'anticorps
MA55818A (fr) Anticorps et immunoconjugués de fr-alpha biparatopique
EP3992209A4 (fr) Anticorps cldn18.2 et son utilisation
MA49846A (fr) Anticorps qui se lient à l'egfr et à cmet
EP3807318A4 (fr) Constructions d'anticorps multi-spécifiques
MA55043A (fr) Anticorps hétérodimériques se liant à l'antigène cd3 et l'antigène cd20
MA48462A (fr) Formulations d'anticorps anti-rankl humains, et leurs méthodes d'utilisation
EP3580239A4 (fr) Anticorps anti-ilt3 et conjugués anticorps-médicament
IL286483A (en) Claudin-6 antibodies and drug conjugates
EP4071172A4 (fr) Anticorps anti-lilrb1 et ses utilisations
EP3294335A4 (fr) Anticorps anti-fcrn à maturation d'affinité humanisés
WO2018075692A3 (fr) Constructions d'anticorps
EP3904382A4 (fr) Anticorps anti-il-23p19 et ses utilisations
EP3758737A4 (fr) Anticorps anti-il-6 et constructions de fusion et conjugués associés
EP3443012A4 (fr) Anticorps anti-axl, fragments d'anticorps et leurs immunoconjugués et utilisations associées